Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Lupin Launches Generic Tricor Tablets In US

Pharma major Lupin Ltd., said its subsidiary Lupin Pharmaceuticals Inc. had launched its Fenofibrate tablets in 48 mg and 145 mg strengths in the US, for which it had received final approval from the US FDA.

Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's Tricor tablets and are indicated for primary hypercholesterolemia or mixed dyslipidemia and severe hypertriglyceridemia.

Abbott's Tricor tables, 48 mg and 145 mg, had sales of $1.26 billion as per IMS Health, June 2012.

Commenting on the approval, Lupin Pharmaceuticals CEO and Group President Vinita Gupta said, "We are very happy to bring this product to market in the US. Patients can be assured that they are receiving the same high quality product they have been accustomed to a a more affordable price."

At the BSE, Lupin shares are currently trading at Rs.565.50, up 0.60 percent from the previous close.

Click here to receive FREE breaking news email alerts for Lupin Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.